Early Adopter Strategy DTU is not yet commercially available. Target select academic medical centers and trauma units for pre‑sales pilots to validate performance, collect clinician feedback, and build KOLs to accelerate broader adoption once clearance is achieved.

Strategic Partnerships With a lean team and a new Executive VP of Business Development, pursue partnerships with large medical device companies or distribution networks to scale commercialization, fund trials, and navigate regulatory and reimbursement pathways.

Competitive Differentiation Position DTU as a faster, more precise alternative to RF and Harmonic solutions for vessel sealing and hemostasis. Develop clinical demonstrations and comparative data to support procurement discussions and stand out in a crowded market dominated by Olympus, Stryker, Medtronic, and others.

Credibility Signals Leverage UW spinout pedigree and prior Regulation Crowdfunding activity as credibility signals in sales discussions. Use investor and academic validation to reduce perceived risk when proposing pilot programs and co-investment opportunities with hospitals.

Clinical Workflow Fit Focus on surgical and trauma workflows that benefit from rapid bleeding control. Prepare targeted value propositions for trauma bays and operating rooms, including training plans and integration with existing devices to minimize disruption and speed adoption.